Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | suspended | Phase 2 | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07581405 | GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer | not yet recruiting | Phase 2 | 26 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 |
| clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | not yet recruiting | Phase 2 | 35 | Mark BernardOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06826079 | Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer(SNCCTGC) | recruiting | Phase 2 | 86 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07025889 | IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer | recruiting | Phase 1 / Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07768514 | Maxigesic for Postoperative Pain Control After Laparoscopic or Robotic Gastrectomy | active not recruiting | Phase 2 | 90 | Seoul National University Bundang HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 97 | NextCure, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04354662 | Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer | completed | Phase 2 | 51 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05468138 | PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery | active not recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06792435 | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | active not recruiting | Phase 1 / Phase 2 | 240 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757165 | The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy(ESMGC) | recruiting | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07101666 | Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer(TNT-SHORT) | not yet recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06447636 | Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06921928 | Study for AZD4360 in Participants With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 31 | AstraZenecaINDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT00183898 | Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03641313 | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.(FORTITUDE-103) | terminated | Phase 1 / Phase 2 | 72 | AmgenINDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | recruiting | Phase 2 | 226 | AstraZenecaINDUSTRY | 14 | Jul 29, 2026 | clinicaltrials |
| NCT07509008 | Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum | not yet recruiting | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06914687 | Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer(LOGICAN) | active not recruiting | Phase 2 | 118 | UNICANCEROTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05771584 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer(Conerstone3) | active not recruiting | Phase 2 | 24 | Aston Sci. Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT04164979 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 2 | 34 | University of California, IrvineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07692204 | A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 30 | SanofiINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07709767 | Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 21 | Tang-Du HospitalOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07701681 | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 75 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04840264 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | recruiting | Phase 2 | 79 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07689292 | Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma(SKB264-Fru-GA) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07692334 | Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 28 | West China Second University HospitalOTHER | 0 | Jul 9, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials